Cover Image

Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials

Mutahir Tunio,1 Mushabbab Al Asiri,1 Abdulrehman Al Hadab,1 Yasser Bayoumi2 1Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia; 2Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt Background: A meta-analysis was conducted to ass...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tunio M (Author), Al Asiri M (Author), Al Hadab A (Author), Bayoumi Y (Author)
Format:	Book
Published:	Dove Medical Press, 2015-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment
by: Gaku Yamamichi, et al.
Published: (2024)

FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer
by: Astrid Børretzen, et al.
Published: (2019)

Response and Resistance in Castration-Resistant Prostate Cancer
Published: (2020)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
by: Yi-Ting Lin, et al.
Published: (2021)

Supraclavicular Lymphadenopathy: Initial Manifestation of Metastasis in Carcinoma of Cervix
by: Mutahir A. Tunio, et al.
Published: (2013)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
by: Brandon Bumbaca, et al.
Published: (2018)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019)

Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
by: Faiza Naseer, et al.
Published: (2021)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Kan Wu, et al.
Published: (2021)

Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer
by: Meenakshi Meenu, MBBS, MD, DM, et al.
Published: (2020)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
by: Bretoni A, et al.
Published: (2019)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
by: Huang Y, et al.
Published: (2022)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
by: Channing J Paller, et al.
Published: (2011)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
by: Bretoni A, et al.
Published: (2019)

Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin
by: Jianwei Zheng, et al.
Published: (2020)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
by: Dan Su, et al.
Published: (2021)

Predictive factors for bone metastasis in patients with prostate cancer
by: Reydienis Ricardo Infante Cedeño, et al.
Published: (2023)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
by: Mukherji D, et al.
Published: (2014)

Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials
by: Yang Liu, et al.
Published: (2023)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
by: Junru Chen, et al.
Published: (2022)

Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments
by: Baokai Dou, et al.
Published: (2024)

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
by: Yulu Zhang, et al.
Published: (2024)

Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies
by: Rajeev K. Singla, et al.
Published: (2021)

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer
by: Jie Zeng, et al.
Published: (2023)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
by: Joana Simões, et al.
Published: (2018)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
by: Yuto Baba, et al.
Published: (2022)

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis
by: Mei-Chi Su, et al.
Published: (2024)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019)

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
by: Bevin C English, et al.
Published: (2010)

Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Xin Wang, et al.
Published: (2020)

Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
by: Koran S. Harris, et al.
Published: (2017)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
by: Jean-Marc Ferrero, et al.
Published: (2023)

Embelin, a small molecule quinone with a co-clinical power for castrate-resistant prostate cancer
by: Dr. Radhika J Poojari
Published: (2014)

Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation
by: Yang C, et al.
Published: (2017)

MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?
by: Mariana Ferreira, et al.
Published: (2024)

Obstructive Small Bowel Metastasis from Uterine Leiomyosarcoma: A Case Report
by: Mutahir A. Tunio, et al.
Published: (2014)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
by: Xiaohui Zeng, et al.
Published: (2022)